Codexis reported an EPS of -$0.17 in its last earnings report, beating expectations of -0.214. Codexiss price range in the past 12 months was $2.19..

Codexis Documentary Showcases its Specialized Capabilities Engineering High Performance Enzymes to Enable Delivery of Novel Therapeutics. Codexis is developing its proprietary ECO Synthesis™ platform to enable the scaled manufacture of RNAi therapeutics. Codexis Inc. (CDXS) stock price today, quote & news | seeking alpha. Join the Summer Sale! Skip the content Skip to content. Codexis reported an EPS of -$0.17 in its last earnings report, beating expectations of -0.214. Codexis has 69,803,990 shares outstanding. Codexiss price range in the past 12 months was $2.19. Codexis reports second quarter 2023 financial results. Codexis reiterates its 20th financial guidance issued on July 20, 2023. Product revenues are expected to be in the range of $30 million to $35 million. Codexis delivered earnings and revenue surprises of 19.05% and 0.84% for the quarter ended June 2023. Codexis pulled back from biotherapeutics as it cuts staff by 25%. The company, which signed a lease two years ago in San Carlos, will consolidate its staff at its Redwood City headquarters. Codexis, Inc. reports financial results for the second quarter ended June 30, 2023. Codexis to Participate in Jefferies 2023 Healthcare Conference, being held June 7-9, in New York, New York.